NPM1 mutation

Clinical Activity is Induced by Ziftomenib in NPM1-mutant R/R AML

Source – Kura Oncology Phase I data from the KOMET-001 trial (NCT04067336) showed that treatment with Ziftomenib, a menin-MLL (KMT2A) ...